File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: Identification of local and circulating cancer stem cells in human liver cancer
  • Basic View
  • Metadata View
  • XML View
TitleIdentification of local and circulating cancer stem cells in human liver cancer
 
AuthorsZhen, FY1
Ngai, P
Ho, DW
Wan, CY
Ng, MNP
Chi, KL
Li, MLY
Ka, HT
Chi, TL
Poon, RTP
Sheung, TF1
 
Issue Date2008
 
PublisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www.hepatology.org/
 
CitationHepatology, 2008, v. 47 n. 3, p. 919-928 [How to Cite?]
DOI: http://dx.doi.org/10.1002/hep.22082
 
AbstractIncreasing evidence has revealed the importance of cancer stem cells (CSCs) in carcinogenesis. Although liver CSCs have been identified in hepatocellular carcinoma (HCC) cell lines, no data have shown the presence of these cells in human settings. The present study was designed to delineate CSCs serially from HCC cell lines, human liver cancer specimens to blood samples, using CD90 as a potential marker. The number of CD90+ cells increased with the tumorigenicity of HCC cell lines. CD45-CD90+ cells were detected in all the tumor specimens, but not in the normal, cirrhotic, and parallel nontumorous livers. In addition, CD45-CD90+ cells were detectable in 90% of blood samples from liver cancer patients, but none in normal subjects or patients with cirrhosis. A significant positive correlation between the number of CD45-CD90+ cells in the tumor tissues and the number of CD45-CD90+ cells in the blood samples was identified. CD90+ cells sorted from cell lines and CD45-CD90+ cells from the tumor tissues and blood samples of liver cancer patients generated tumor nodules in immunodeficient mice. Serial transplantation of CD90+ cells from tumor xenografts generated tumor nodules in a second and subsequently third batch of immunodeficient mice. Treatment of CD90+ CSCs with anti-human CD44 antibody induced cell apoptosis in a dose-dependent manner. Conclusion: Identification of CD45 -CD90+ CSCs in both tumor tissues and circulation suggests that CD45-CD90+ could be used as a marker for human liver cancer and as a target for the diagnosis and therapy of this malignancy. Copyright © 2007 by the American Association for the Study of Liver Diseases.
 
ISSN0270-9139
2013 Impact Factor: 11.190
 
DOIhttp://dx.doi.org/10.1002/hep.22082
 
ISI Accession Number IDWOS:000253698900018
 
ReferencesReferences in Scopus
 
DC FieldValue
dc.contributor.authorZhen, FY
 
dc.contributor.authorNgai, P
 
dc.contributor.authorHo, DW
 
dc.contributor.authorWan, CY
 
dc.contributor.authorNg, MNP
 
dc.contributor.authorChi, KL
 
dc.contributor.authorLi, MLY
 
dc.contributor.authorKa, HT
 
dc.contributor.authorChi, TL
 
dc.contributor.authorPoon, RTP
 
dc.contributor.authorSheung, TF
 
dc.date.accessioned2010-09-06T08:39:43Z
 
dc.date.available2010-09-06T08:39:43Z
 
dc.date.issued2008
 
dc.description.abstractIncreasing evidence has revealed the importance of cancer stem cells (CSCs) in carcinogenesis. Although liver CSCs have been identified in hepatocellular carcinoma (HCC) cell lines, no data have shown the presence of these cells in human settings. The present study was designed to delineate CSCs serially from HCC cell lines, human liver cancer specimens to blood samples, using CD90 as a potential marker. The number of CD90+ cells increased with the tumorigenicity of HCC cell lines. CD45-CD90+ cells were detected in all the tumor specimens, but not in the normal, cirrhotic, and parallel nontumorous livers. In addition, CD45-CD90+ cells were detectable in 90% of blood samples from liver cancer patients, but none in normal subjects or patients with cirrhosis. A significant positive correlation between the number of CD45-CD90+ cells in the tumor tissues and the number of CD45-CD90+ cells in the blood samples was identified. CD90+ cells sorted from cell lines and CD45-CD90+ cells from the tumor tissues and blood samples of liver cancer patients generated tumor nodules in immunodeficient mice. Serial transplantation of CD90+ cells from tumor xenografts generated tumor nodules in a second and subsequently third batch of immunodeficient mice. Treatment of CD90+ CSCs with anti-human CD44 antibody induced cell apoptosis in a dose-dependent manner. Conclusion: Identification of CD45 -CD90+ CSCs in both tumor tissues and circulation suggests that CD45-CD90+ could be used as a marker for human liver cancer and as a target for the diagnosis and therapy of this malignancy. Copyright © 2007 by the American Association for the Study of Liver Diseases.
 
dc.description.natureLink_to_subscribed_fulltext
 
dc.identifier.citationHepatology, 2008, v. 47 n. 3, p. 919-928 [How to Cite?]
DOI: http://dx.doi.org/10.1002/hep.22082
 
dc.identifier.doihttp://dx.doi.org/10.1002/hep.22082
 
dc.identifier.epage928
 
dc.identifier.hkuros140961
 
dc.identifier.isiWOS:000253698900018
 
dc.identifier.issn0270-9139
2013 Impact Factor: 11.190
 
dc.identifier.issue3
 
dc.identifier.openurl
 
dc.identifier.pmid18275073
 
dc.identifier.scopuseid_2-s2.0-40949160140
 
dc.identifier.spage919
 
dc.identifier.urihttp://hdl.handle.net/10722/83328
 
dc.identifier.volume47
 
dc.languageeng
 
dc.publisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www.hepatology.org/
 
dc.publisher.placeUnited States
 
dc.relation.ispartofHepatology
 
dc.relation.referencesReferences in Scopus
 
dc.rightsHepatology. Copyright © John Wiley & Sons, Inc.
 
dc.titleIdentification of local and circulating cancer stem cells in human liver cancer
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Zhen, FY</contributor.author>
<contributor.author>Ngai, P</contributor.author>
<contributor.author>Ho, DW</contributor.author>
<contributor.author>Wan, CY</contributor.author>
<contributor.author>Ng, MNP</contributor.author>
<contributor.author>Chi, KL</contributor.author>
<contributor.author>Li, MLY</contributor.author>
<contributor.author>Ka, HT</contributor.author>
<contributor.author>Chi, TL</contributor.author>
<contributor.author>Poon, RTP</contributor.author>
<contributor.author>Sheung, TF</contributor.author>
<date.accessioned>2010-09-06T08:39:43Z</date.accessioned>
<date.available>2010-09-06T08:39:43Z</date.available>
<date.issued>2008</date.issued>
<identifier.citation>Hepatology, 2008, v. 47 n. 3, p. 919-928</identifier.citation>
<identifier.issn>0270-9139</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/83328</identifier.uri>
<description.abstract>Increasing evidence has revealed the importance of cancer stem cells (CSCs) in carcinogenesis. Although liver CSCs have been identified in hepatocellular carcinoma (HCC) cell lines, no data have shown the presence of these cells in human settings. The present study was designed to delineate CSCs serially from HCC cell lines, human liver cancer specimens to blood samples, using CD90 as a potential marker. The number of CD90+ cells increased with the tumorigenicity of HCC cell lines. CD45-CD90+ cells were detected in all the tumor specimens, but not in the normal, cirrhotic, and parallel nontumorous livers. In addition, CD45-CD90+ cells were detectable in 90% of blood samples from liver cancer patients, but none in normal subjects or patients with cirrhosis. A significant positive correlation between the number of CD45-CD90+ cells in the tumor tissues and the number of CD45-CD90+ cells in the blood samples was identified. CD90+ cells sorted from cell lines and CD45-CD90+ cells from the tumor tissues and blood samples of liver cancer patients generated tumor nodules in immunodeficient mice. Serial transplantation of CD90+ cells from tumor xenografts generated tumor nodules in a second and subsequently third batch of immunodeficient mice. Treatment of CD90+ CSCs with anti-human CD44 antibody induced cell apoptosis in a dose-dependent manner. Conclusion: Identification of CD45 -CD90+ CSCs in both tumor tissues and circulation suggests that CD45-CD90+ could be used as a marker for human liver cancer and as a target for the diagnosis and therapy of this malignancy. Copyright &#169; 2007 by the American Association for the Study of Liver Diseases.</description.abstract>
<language>eng</language>
<publisher>John Wiley &amp; Sons, Inc. The Journal&apos;s web site is located at http://www.hepatology.org/</publisher>
<relation.ispartof>Hepatology</relation.ispartof>
<rights>Hepatology. Copyright &#169; John Wiley &amp; Sons, Inc.</rights>
<title>Identification of local and circulating cancer stem cells in human liver cancer</title>
<type>Article</type>
<identifier.openurl>http://library.hku.hk:4550/resserv?sid=HKU:IR&amp;issn=0270-9139&amp;volume=47&amp;issue=3&amp;spage=919&amp;epage=928&amp;date=2008&amp;atitle=Identification+of+local+and+circulating+cancer+stem+cells+in+human+liver+cancer</identifier.openurl>
<description.nature>Link_to_subscribed_fulltext</description.nature>
<identifier.doi>10.1002/hep.22082</identifier.doi>
<identifier.pmid>18275073</identifier.pmid>
<identifier.scopus>eid_2-s2.0-40949160140</identifier.scopus>
<identifier.hkuros>140961</identifier.hkuros>
<relation.references>http://www.scopus.com/mlt/select.url?eid=2-s2.0-40949160140&amp;selection=ref&amp;src=s&amp;origin=recordpage</relation.references>
<identifier.volume>47</identifier.volume>
<identifier.issue>3</identifier.issue>
<identifier.spage>919</identifier.spage>
<identifier.epage>928</identifier.epage>
<identifier.isi>WOS:000253698900018</identifier.isi>
<publisher.place>United States</publisher.place>
</item>
Author Affiliations
  1. The University of Hong Kong